KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $6.02 $13.63 Friday, 26th Apr 2024 VERV stock ended at $6.16. This is 0.96% less than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 6.47% from a day low at $6.02 to a day high of $6.41.
90 days $6.02 $19.34
52 weeks $6.02 $21.42

Historical Verve Therapeutics, Inc. prices

Date Open High Low Close Volume
Jan 09, 2024 $13.76 $14.32 $13.57 $13.92 873 405
Jan 08, 2024 $13.21 $14.00 $12.80 $13.93 1 128 682
Jan 05, 2024 $13.67 $13.67 $12.58 $13.32 1 057 780
Jan 04, 2024 $13.05 $13.90 $12.86 $13.61 870 915
Jan 03, 2024 $13.65 $13.94 $12.78 $13.00 1 289 355
Jan 02, 2024 $13.82 $14.86 $13.74 $14.00 1 188 617
Dec 29, 2023 $14.94 $14.94 $13.74 $13.94 1 467 484
Dec 28, 2023 $14.60 $15.03 $14.55 $14.95 1 002 719
Dec 27, 2023 $15.11 $15.34 $14.30 $14.67 797 984
Dec 26, 2023 $14.71 $15.02 $14.48 $14.81 726 655
Dec 22, 2023 $14.39 $15.01 $14.20 $14.29 1 298 121
Dec 21, 2023 $14.06 $14.56 $13.57 $14.09 928 639
Dec 20, 2023 $14.43 $14.84 $13.54 $13.58 1 107 763
Dec 19, 2023 $13.86 $14.47 $13.67 $14.30 1 144 946
Dec 18, 2023 $13.86 $14.13 $13.41 $13.52 861 231
Dec 15, 2023 $14.53 $15.00 $13.56 $13.86 1 930 234
Dec 14, 2023 $13.98 $14.75 $13.78 $14.32 2 388 484
Dec 13, 2023 $12.08 $13.44 $11.86 $13.31 1 280 882
Dec 12, 2023 $12.48 $12.48 $11.97 $12.12 998 817
Dec 11, 2023 $12.77 $12.87 $12.27 $12.41 1 030 048
Dec 08, 2023 $12.81 $13.43 $12.52 $12.79 1 153 961
Dec 07, 2023 $12.38 $12.96 $12.13 $12.91 1 396 611
Dec 06, 2023 $12.18 $13.24 $11.83 $12.49 2 319 334
Dec 05, 2023 $11.80 $11.84 $11.36 $11.57 1 241 238
Dec 04, 2023 $11.78 $12.28 $11.38 $12.01 1 394 284
Click to get the best stock tips daily for free!

About Verve Therapeutics, Inc.

Verve Therapeutics. Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with... VERV Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT